Inactivation

Global Seasonal Influenza Vaccine Research Report 2023: Trivalent vs. Quadrivalent, Injection vs. Nasal Spray - Market Forecasts to 2029 - ResearchAndMarkets.com

Retrieved on: 
Friday, November 17, 2023
Infectious Diseases, Pharmaceutical, Health, World Health Organization, Inactivation, Research, Distribution, Market, Pediatrics, Healthcare Facilities Accreditation Program, Porter W. Anderson Jr., WHO, Hospital, Vaccination, Weather, Death, SWOT, Vaccine, USD, Influenza, Fatality, Porter's five forces analysis, Country, Government, Anthrax Vaccine Immunization Program, Research report, Retail, Pharmacy

The Global Seasonal Influenza Vaccine Market is poised to reach USD 9.3 Billion by 2029, a significant increase from the 2022 figure of USD 5.8 Billion.

Key Points: 
  • The Global Seasonal Influenza Vaccine Market is poised to reach USD 9.3 Billion by 2029, a significant increase from the 2022 figure of USD 5.8 Billion.
  • Over the forecast period from 2024 to 2029, the Global Seasonal Influenza Vaccines market is anticipated to grow at a steady CAGR of 7.61%.
  • Several factors contribute to the favorable growth of the Global Seasonal Influenza Vaccine market.
  • The report presents the analysis of Seasonal Influenza Vaccine Market for the historical period of 2019-2022, the estimated year 2023 and the forecast period of 2024-2029
    The report analyses the Seasonal Influenza Vaccine Market by Valency (Quadrivalent, Trivalent)
    The report analyses the Seasonal Influenza Vaccine Market by Age Group (Pediatrics, Adults, Elderly)
    The report analyses the Seasonal Influenza Vaccine Market by Distribution Channel (Hospitals, Pharmacies, Government Supply)
    The key insights of the report have been presented through the frameworks of SWOT and Porter's Five Forces Analysis.

Vaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, May 9, 2023
Migraine, Inactivation, PD, Senior, Comparison, Half-life, COVID-19, American Academy, CGRP, Brain, Messenger, Congress, Immunity, Patient, Investment, LDL, PCSK9, Neurology, Adenoviridae, Safety, Infection, Pharmaceutical industry, Management, Vaccine, Cryptocurrency, Research

CAPE CANAVERAL, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.

Key Points: 
  • CAPE CANAVERAL, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.
  • “Vaxxinity remains on track to meet critical milestones in 2023, having taken our fifth program to the clinic with VXX-401, our investigational anti-PCSK9 vaccine for lowering cholesterol.
  • This represents another opportunity to demonstrate the clinical potential of our Vaxxine platform,” said Mei Mei Hu, Chief Executive Officer of Vaxxinity.
  • General and administrative expenses were $7.4 million and $6.7 million for the three months ended March 31, 2023 and 2022, respectively.

Vaxxinity to Present at World Vaccine Congress, American Academy of Neurology, and BNA2023 Festival of Neuroscience in April

Retrieved on: 
Tuesday, March 28, 2023
Inactivation, British Neuroscience Association, Human services, United States Department of Health and Human Services, COVID-19, Messenger, Congress, Public health, Immunity, Adenoviridae, Pharmaceutical industry, Vaccine, Science, Neuroscience

CAPE CANAVERAL, Fla., March 28, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that members of its leadership team will present data on investigational vaccines for COVID-19 and neurodegenerative diseases at three upcoming scientific and medical conferences in April.

Key Points: 
  • Vaxxinity CEO Mei Mei Hu to participate in fireside chat with Sarah Despres, Counselor to the Secretary for Public Health and Science, U.S. Department of Health and Human Services, at World Vaccine Congress
    CAPE CANAVERAL, Fla., March 28, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that members of its leadership team will present data on investigational vaccines for COVID-19 and neurodegenerative diseases at three upcoming scientific and medical conferences in April.
  • World Vaccine Congress (April 3-6, 2023)
    Title: Success in Boosting the Immunity by Vaxxinity's UB-612 Compared to the mRNA, Adenovirus and Inactivated COVID-19 Vaccine Platforms
    AAN Annual Meeting (April 22-27, 2023)
    British Neuroscience Association 2023 Festival of Neuroscience (April 23-26, 2023)

Veterinary Pain Management Market worth $2.5 billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, September 22, 2022
Knowledge, Chanelle Pharma Novice Hurdle, GEM, Adoption, Temperature, Lists of diseases, Brain, Dechra Pharmaceuticals, Prevalence, Nonsteroidal anti-inflammatory drug, Poultry, Inactivation, Overweight, Merck & Co., Population, Osteoarthritis, USD, Cancer, Intelligence, Pain, Rabies, SME, Arthralgia, Tissue, Livestock, Research, Pain management, PETS, CAGR, Vaccine, Marketing, Aquaculture, Toxoid, Coccidiosis, Brucellosis, Technology, Disease

In this report, the veterinary pain management market has been segmented by product, application, animal type, end user, and region.

Key Points: 
  • In this report, the veterinary pain management market has been segmented by product, application, animal type, end user, and region.
  • In 2021, the NSAIDs segment accounted for largest share of the veterinary pain management drugs market.
  • The veterinary pain management drugs market is segment into oral, parenteral, and topical on the basis of route of administration.
  • Based on applications, the veterinary pain management market is segmented into joint pain, post-operative pain, cancer, and other applications.

Insights on the Vaccine Contract Manufacturing Global Market to 2027 - Featuring Ajinomoto Althea, Catalent and IDT Biologika Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 29, 2021
Health, Infectious Diseases, Other Science, Clinical Trials, Research, Science, Pharmaceutical, Growth, Vaccine, COVID-19, Subunit, Inactivation, CAGR, Video game

The "Vaccine Contract Manufacturing - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Vaccine Contract Manufacturing - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Attenuated, one of the segments analyzed in the report, is projected to record a 7.8% CAGR and reach US$1.6 Billion by the end of the analysis period.
  • The U.S. Market is Estimated at $672.6 Million, While China is Forecast to Grow at 12.1% CAGR
    The Vaccine Contract Manufacturing market in the U.S. is estimated at US$672.6 Million in the year 2020.
  • In the global Subunit-based segment, USA, Canada, Japan, China and Europe will drive the 7.8% CAGR estimated for this segment.

$185+ Bn Vaccine (Inactivated, Live Attenuated, Subunit Vaccines) Markets, 2028 by Indication, Route of Administration, Type, Valence - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 14, 2021
Health, Other Health, Organization, Government, Route of administration, Immunization, Monovalence, Immunity, Administration, COVID-19, Intramuscular injection, Growth, Industry, Streptococcus pneumoniae, Polyvalency (chemistry), COVID-19 vaccine, Vaccine, CAGR, Hepatitis, Prevalence, Coronavirus, Inactivated vaccine, Antigen, Inactivation, Pharmaceutical industry, Aquaculture, Rotavirus

The vaccine market's growth is mainly attributed to the high prevalence of diseases, technological advancements in the vaccines industry, increasing government initiatives towards immunization, and a strong pipeline for vaccines.

Key Points: 
  • The vaccine market's growth is mainly attributed to the high prevalence of diseases, technological advancements in the vaccines industry, increasing government initiatives towards immunization, and a strong pipeline for vaccines.
  • In addition, emerging markets are expected to offer significant growth opportunities for players operating in the vaccines market.
  • However, product recalls and inadequate access to vaccines are the key factors expected to hinder the growth of the vaccines market.
  • Based on the disease indication, in 2021, the COVID-19 vaccines segment is estimated to account for the largest share of the total vaccines market.

Seevix Material Sciences Synthetic SVX Spidersilk to Be Used in Filters to Neutralize COVID-19

Retrieved on: 
Monday, May 11, 2020
SVX, Scallion virus X, Fibril, Air filter, Water filter, Inactivation, Separation processes, Gases, Nature

JERUSALEM, May 11, 2020 /PRNewswire/ -- Seevix Material Sciences Ltd., which develops and manufactures synthetic SVX spidersilk, announced today that it plans to use its patented spidersilk technology to create disposable and safe filters with high entrapment and inactivation efficacy to neutralize COVID-19 and other coronaviruses.

Key Points: 
  • JERUSALEM, May 11, 2020 /PRNewswire/ -- Seevix Material Sciences Ltd., which develops and manufactures synthetic SVX spidersilk, announced today that it plans to use its patented spidersilk technology to create disposable and safe filters with high entrapment and inactivation efficacy to neutralize COVID-19 and other coronaviruses.
  • The binding peptide can be quickly adapted to other viruses and mutating viral strains.
  • SVX fibers with the specific peptide sequence can be incorporated in textiles used in filters, used to coat the external surface of textiles, or form part of a protective insert to entrap and neutralize viruses and microbes.
  • Seevix manufactures SVX by means of a fermenter-based, sustainable, single-step biomimicry process, inducing the self-assembly of protein building blocks into nano-fibrils.